These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 31652029)

  • 1. Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to Physiologically-Based Pharmacokinetic Modeling and Simulation.
    Kuemmel C; Yang Y; Zhang X; Florian J; Zhu H; Tegenge M; Huang SM; Wang Y; Morrison T; Zineh I
    CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):21-28. PubMed ID: 31652029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspective on model-informed drug development.
    Lesko LJ
    CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1127-1129. PubMed ID: 34404115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future.
    Rowland Yeo K; Gil Berglund E; Chen Y
    Clin Pharmacol Ther; 2024 Sep; 116(3):563-576. PubMed ID: 38686708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?
    Frechen S; Rostami-Hodjegan A
    Pharm Res; 2022 Aug; 39(8):1733-1748. PubMed ID: 35445350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity.
    Gaohua L; Miao X; Dou L
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1103-1124. PubMed ID: 34253134
    [No Abstract]   [Full Text] [Related]  

  • 6. Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility.
    Musuamba FT; Skottheim Rusten I; Lesage R; Russo G; Bursi R; Emili L; Wangorsch G; Manolis E; Karlsson KE; Kulesza A; Courcelles E; Boissel JP; Rousseau CF; Voisin EM; Alessandrello R; Curado N; Dall'ara E; Rodriguez B; Pappalardo F; Geris L
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):804-825. PubMed ID: 34102034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities and challenges for applying model-informed drug development approaches to gene therapies.
    Belov A; Schultz K; Forshee R; Tegenge MA
    CPT Pharmacometrics Syst Pharmacol; 2021 Apr; 10(4):286-290. PubMed ID: 33608998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing Computational Model Credibility Using a Risk-Based Framework: Application to Hemolysis in Centrifugal Blood Pumps.
    Morrison TM; Hariharan P; Funkhouser CM; Afshari P; Goodin M; Horner M
    ASAIO J; 2019; 65(4):349-360. PubMed ID: 30973403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-Informed Drug Development in Pediatric Dose Selection.
    Bi Y; Liu J; Li F; Yu J; Bhattaram A; Bewernitz M; Li RJ; Ahn J; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S60-S69. PubMed ID: 34185906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Industry Perspective on Using MIDD for Pediatric Studies Requiring Integration of Ontogeny.
    Corriol-Rohou S; Cheung SYA
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S112-S119. PubMed ID: 31502694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of Model-Informed Drug Development in Dose Selection and Optimization for siRNA Therapies.
    Yuan Y; Li L; Earp J; Ma L; Bhattaram VA; Sharma V; Tong A; Wang Y; Liu J; Zhu H
    J Clin Pharmacol; 2024 Jul; 64(7):799-809. PubMed ID: 38426370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scientific and regulatory evaluation of empirical pharmacometric models: An application of the risk informed credibility assessment framework.
    Skottheim Rusten I; Musuamba FT
    CPT Pharmacometrics Syst Pharmacol; 2021 Nov; 10(11):1281-1296. PubMed ID: 34514745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology.
    Zhang X; Yang Y; Grimstein M; Fan J; Grillo JA; Huang SM; Zhu H; Wang Y
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S160-S178. PubMed ID: 33205429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Model-Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling.
    Bi Y; Liu J; Li L; Yu J; Bhattaram A; Bewernitz M; Li RJ; Liu C; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S104-S111. PubMed ID: 31502691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making.
    Madabushi R; Seo P; Zhao L; Tegenge M; Zhu H
    Pharm Res; 2022 Aug; 39(8):1669-1680. PubMed ID: 35552984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Physiologically Based Pharmacokinetic Modeling and Simulation in Enabling Model-Informed Development of Drugs and Biotherapeutics.
    Arya V; Venkatakrishnan K
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S7-S11. PubMed ID: 33205427
    [No Abstract]   [Full Text] [Related]  

  • 17. Credibility assessment of computational models according to ASME V&V40: Application to the Bologna Biomechanical Computed Tomography solution.
    Aldieri A; Curreli C; Szyszko JA; La Mattina AA; Viceconti M
    Comput Methods Programs Biomed; 2023 Oct; 240():107727. PubMed ID: 37523955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review.
    Loisios-Konstantinidis I; Paraiso RLM; Fotaki N; McAllister M; Cristofoletti R; Dressman J
    J Pharm Pharmacol; 2019 Apr; 71(4):699-723. PubMed ID: 30793317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leveraging model-informed approaches for drug discovery and development in the cardiovascular space.
    Dockendorf MF; Vargo RC; Gheyas F; Chain ASY; Chatterjee MS; Wenning LA
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):355-364. PubMed ID: 29353335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model-informed drug development in pediatric, pregnancy and geriatric drug development: States of the art and future.
    Wu YE; Zheng YY; Li QY; Yao BF; Cao J; Liu HX; Hao GX; van den Anker J; Zheng Y; Zhao W
    Adv Drug Deliv Rev; 2024 Aug; 211():115364. PubMed ID: 38936664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.